Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy

Clinical Drug Investigation

Volumn 20, Issue 2, 2000, Pages 109-121

  Berto, P ^a   Munro, V ^b   Gaddi, A ^c   Negrini, C ^d   Hutton, J ^b   Mast, O ^e  

^a Medtap International Inc ^*

^b MEDTAP International Inc   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Bayer SpA Italy   (Italy)

^e BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; ISCHEMIC HEART DISEASE; ITALY; MODEL; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 0033866572     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020020-00006     Document Type: Article

References (24)

1. Section 37: The probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics
2. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study
3. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Trends in cardiovascular disease mortality in industrialized countries since 1950
6. International trends in coronary heart disease mortality, morbidity, and risk factors
7. High-often-that-high graphs of serum cholesterol: Findings from the Scottish heart and Scottish MONICA studies
8. Antioxidants in the Mediterranean diet
9. Is Italy losing the 'Mediterranean advantage'? Report on the Gubbio population study: Cardiovascular risk factors at baseline. Gubbio Collaborative Study Group
10. Pharmaco-economic aspects of lipid-lowering therapy: Is it worth the price?
11. Simvastatin: A pharmaco-economic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease
12. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment
13. Mean levels and distribution of some cardiovascular risk factors in Italy in the 1970's and the 1980's. The Italian RIFLE Pooling Project. Risk factors and life expectancy
14. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
15. A randomized trial to assess effectiveness and cost in clinical practice: Rationale and design of the cholesterol Redaction Intervention Study (CRIS)
16. By how much and how quickly does reduction in serum cholesterol concentration lower the risk of ischaemic heart disease?
17. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
18. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other societies on coronary prevention
19. Prevention of coronary heart disease in clinical practice: Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension